Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Arcutis today announced that Arcutis management will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026.
-
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at 2026 AAD
-
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at AAD 2026
-
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data in Pediatric Dermatology
-
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
-
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
-
Arcutis today announced that management will participate in the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston.
-
Arcutis today reported financial results for the quarter and year ended December 31, 2025, and provided a business update.
-
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seb Derm to Speak with Their Healthcare Provider
-
WESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...